RecruitingPhase 3NCT06127407
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Studying Chondrosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Servier Bio-Innovation LLC
- Intervention
- Ivosidenib 500mg(drug)
- Enrollment
- 136 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2030
Study locations (30)
- Usc Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Sarcoma Oncology Research Center, Santa Monica, California, United States
- University of Colorado Cancer Center, Aurora, Colorado, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Mayo Clinic - Jacksonville, Fl, Jacksonville, Florida, United States
- University of Miami, Miami, Florida, United States
- Emory Winship Cancer Institute, Atlanta, Georgia, United States
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States
- University of Iowa Hospitals & Clinics- Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic - Rochester, Mn, Rochester, Minnesota, United States
- The Washington University, St Louis, Missouri, United States
- Nebraska Methodist Hospital, Omaha, Nebraska, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Institut de Recherches Internationales Servier
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06127407 on ClinicalTrials.govOther trials for Chondrosarcoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT07360964Clear Cell Chondrosarcoma in ItalyIstituto Ortopedico Rizzoli
- RECRUITINGNCT07315542Diagnostic and Therapeutic Targets in Cartilaginous TumoursSt. Anne's University Hospital Brno, Czech Republic
- RECRUITINGEARLY PHASE1NCT06645808PET-imaging of Two Vartumabs in Patients With Solid TumorsVar2 Pharmaceuticals
- RECRUITINGNCT06486506Proximal Femur Reconstruction Following Resection of Primary Bone Tumors: Analysis of the Clinical and Radiographic ResultsCostantino Errani
- RECRUITINGPHASE2NCT06176989Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsNational Cancer Institute (NCI)
- RECRUITINGNANCT06387485A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative PlanningRicoh USA, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT05836571Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaNational Cancer Institute LAO
- RECRUITINGNANCT05861245Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull BaseQuironsalud